Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA Depot in Primary Progressive Multiple Sclerosis
NCT03362294Phase 2Terminated
- Sponsor
- Mapi Pharma
- Start
- Dec 2017
- Primary completion
- Jun 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of glatiramer acetate in primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Mapi Pharma. Primary endpoint: Safety (Adverse Events and Injection Site Reactions) at 152 weeks. Started Dec 2017; status: terminated.
02
Drugs
glatiramer acetate
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT03362294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362294.